Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Jeffrey S WeberTayla PorettaBrian D StwalleyLeon A SakkalElla X DuTravis WangYan ChenYan WangKeith A BettsAlexander N ShoushtariPublished in: Cancer immunology, immunotherapy : CII (2022)
In patients with resected stage IIIB-C cutaneous melanoma in this ITC, nivolumab improved RFS versus placebo and ipilimumab, and OS versus placebo after post-recurrence survival adjustment.